{"id":"etanercept-acitretin","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"5-15","effect":"Headache"},{"rate":"10-20","effect":"Infections (upper respiratory, sinusitis)"},{"rate":"20-40","effect":"Lipid abnormalities (from acitretin)"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":null,"effect":"Teratogenicity (acitretin)"},{"rate":"15-30","effect":"Dry skin and mucous membranes"}]},"_chembl":{"chemblId":"CHEMBL1201572","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept is a TNF receptor fusion protein that neutralizes tumor necrosis factor-alpha, a key driver of systemic inflammation in psoriasis. Acitretin is a retinoid that modulates gene expression in skin cells, promoting normal differentiation and reducing hyperproliferation. The combination addresses both the underlying immune dysregulation and the abnormal skin cell behavior characteristic of moderate-to-severe psoriasis.","oneSentence":"Etanercept blocks TNF-α signaling while acitretin normalizes keratinocyte differentiation and reduces inflammation, together targeting both immune and skin-barrier dysfunction in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:23.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe plaque psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT01706692","phase":"","title":"Swiss Dermatology Network of Targeted Therapies (SDNTT)","status":"RECRUITING","sponsor":"Swiss Dermatology Network for Targeted Therapies","startDate":"2011-02","conditions":"Psoriasis","enrollment":1121},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT02075697","phase":"","title":"Spanish Registry of Systemic Treatments in Psoriasis","status":"UNKNOWN","sponsor":"Fundación Academia Española de Dermatología","startDate":"2008-10","conditions":"Psoriasis","enrollment":3500},{"nctId":"NCT02330380","phase":"","title":"Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2013-04","conditions":"Psoriasis, Inflammation","enrollment":26},{"nctId":"NCT01812954","phase":"","title":"Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis","status":"COMPLETED","sponsor":"Jochen Schmitt.","startDate":"2013-03","conditions":"Psoriasis","enrollment":1},{"nctId":"NCT00832364","phase":"PHASE4","title":"Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis","status":"WITHDRAWN","sponsor":"Stiefel, a GSK Company","startDate":"2009-10","conditions":"Plaque Psoriasis","enrollment":""},{"nctId":"NCT00156247","phase":"PHASE2","title":"Acitretin and Etanercept in Psoriasis","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-09","conditions":"Psoriasis","enrollment":10},{"nctId":"NCT01233583","phase":"","title":"Regulatory T-cells in Psoriasis Patients as Targets for Therapy","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"2010-06","conditions":"Psoriasis","enrollment":38},{"nctId":"NCT00936065","phase":"PHASE4","title":"Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-07","conditions":"Moderate to Severe Psoriasis","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Etancercept 25mg and Acitretin 10mg"],"phase":"marketed","status":"active","brandName":"Etanercept + Acitretin","genericName":"Etanercept + Acitretin","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etanercept blocks TNF-α signaling while acitretin normalizes keratinocyte differentiation and reduces inflammation, together targeting both immune and skin-barrier dysfunction in psoriasis. Used for Moderate-to-severe plaque psoriasis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}